Analysis: In most of the Big Pharma world, R&D spending towers over revenue from new drugs. Guess who beat the odds
It’s always been the case that there’s no medicine less useful than one that doesn’t make it to patients (unless you regard the task of R&D to be perpetually learning about swimming, while under water…). Yet, launching new medicines that physicians want, that payers will cover, and that patients will take, is a discipline that is unevenly distributed among the big players.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,300+ biopharma pros reading Endpoints daily — and it's free.